Patents by Inventor Meriah Neissel Valente

Meriah Neissel Valente has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
    Publication number: 20230250063
    Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 10, 2023
    Inventors: James A. Johnson, Zulan Pi, Nicholas R. Wurtz, Joanne M. Smallheer, Meriah Neissel Valente, Ellen K. Kick, Charles G. Clark, Pravin Sudhaka Shirude, Balaji Kumar Seshadri, Amit Kumar Chattopadhyay
  • Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
    Patent number: 11180490
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Nicholas R. Wurtz, Meriah Neissel Valente, Karen A. Rossi, Ellen K. Kick
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 11059818
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Carol Hui Hu, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • Triazolopyridine inhibitors of myeloperoxidase and/or EPX
    Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20200291015
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 17, 2020
    Inventors: Joanne M. Smallheer, Carol Hui HU, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX
    Publication number: 20200291016
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 17, 2020
    Inventors: Ellen K. Kick, Joanne M. Smalheer, Scott A. Shaw, Benjiman P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS
    Publication number: 20200199113
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 25, 2020
    Inventors: Joanne M. Smallheer, Nicholas R. Wurtz, Meriah Neissel Valente, Karen A. Rossi, Ellen K. Kick
  • Macrocyclic inhibitors of myeloperoxidase
    Patent number: 10577383
    Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Ellen K. Kick, Meriah Neissel Valente, Carol Hui Hu, Oz Scott Halpern, Sutjano Jusuf
  • MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20190177340
    Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: June 26, 2017
    Publication date: June 13, 2019
    Inventors: Joanne M. Smallheer, Ellen K. Kick, Meriah Neissel Valente, Carol Hui Hu, Oz Scott Halpern, Sutjano Jusuf
  • Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
    Patent number: 9920075
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf
  • TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20170247396
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 31, 2017
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf